Viral Clearance Market Worth $724.5 Million by 2023

CHICAGO, September 14, 2018 /PRNewswire/ --

According to a new market research report "Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023", published by MarketsandMarkets™, the global market is expected to reach USD 724.5 million by 2023 from USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period (2018-2023). The key factors driving the growth of this market include growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and the high incidence and large economic burden of chronic diseases.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

For more Insights on this report, Speak to Our Analyst: 

https://www.marketsandmarkets.com/speaktoanalyst.asp?id=62681197

By application, the recombinant proteins segment is expected to account for the largest share of the market in 2018 

On the basis of application, the global market is segmented into four categories recombinant proteins, blood and blood products, vaccines, and other applications. In 2018, the recombinant proteins segment is expected to account for the largest share of the Viral Clearance Market owing to the high potential of recombinant proteins to treat various diseases, fewer side effects, and shorter development time as compared to small molecules. Furthermore, the regulatory requirement to demonstrate the capacity of the purification process to effectively clear infectious viruses during the manufacturing of recombinant proteins is also expected to support the growth of this market segment during the forecast period.

Browse in-depth TOC on "Viral Clearance Market"

118 - Tables  

33 - Figures  

159 - Pages  

By end user, the pharmaceutical & biotechnology companies' segment is expected to account for the largest share of the market in 2018 

By end user, the Viral Clearance Market is segmented into pharmaceutical & biotechnology companies, CROs, academic research institutes, and other end users. In 2018, the pharmaceutical & biotechnology companies' segment is expected to account for the largest share of the global market. The large share of this segment can be attributed to the rapid expansion of the biopharmaceutical industry, growth in the number of research activities in life sciences, increasing R&D investments in drug development, and increasing number of drug launches.

https://www.marketsandmarkets.com/Market-Reports/viral-clearance-market-62681197.html

By method, the viral removal segment is expected to account for the largest share of the market in 2018 

On the basis of method, the Viral Clearance Market is segmented into viral removal and viral inactivation. In 2018, the viral removal segment is expected to account for the largest share of the global market due to the growth in biopharmaceutical R&D activities; the high acceptance of this method; and the accuracy, speed, and flexibility provided by the method in life sciences research.

The key players in the global Viral Clearance Market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).

Request for PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=62681197

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/viral-clearance-market.asp